Sentences with phrase «placebo patients»
"Placebo patients" refers to individuals who are given a dummy or inactive treatment (such as a sugar pill) rather than an actual medicine or intervention. They serve as a control group in medical experiments or studies to compare the effectiveness of the treatment being tested. Full definition
About 69.9 percent of angiotensin II patients achieved the primary endpoint versus 23.4 percent of placebo patients.
benzinga.com
Fred Hayden of the University of Virginia at Charlottesville says both Tamiflu and placebo patients in the randomised controlled trials were also on paracetamol (acetaminophen), so the two were indeed compared.
(Later, seven of eight placebo patients chose to receive MDMA as well.)
The pill - placebo patients also reported a slight improvement in symptoms, whereas the gabapentin pill group reported a worsening.
All remaining placebo patients crossed over to the guselkumab arm at week 24.
In a 1999 government - sponsored analysis, nonbenzodiazepines caused patients to sleep better and longer than those who took the placebos
At this point, 72 percent of enzalutamide patients and 63 percent of placebo patients were alive at the trial cutoff date showing a 29 percent overall improvement in survival.
The primary findings of the study reported in the New England Journal of Medicine in 2013, showed no differences for alogliptin versus placebo patients in the major endpoint of cardiovascular death, heart attack or stroke.
On safety, too, the angiotensin II patients fared better than the placebo patients.
After 24 weeks, the placebo patients were switched to either the 3g / day or 6g / day dosage, while the treated groups continued at the same dosages.
In addition, topiramate patients reported more abstinent days than placebo patients.
In total, 15 % of rucaparib patients discontinued therapy due to adverse events, compared with 2 % of placebo patients.
At 12 months, 58 % of pemetrexed patients survived, compared with 45 % of placebo patients; at 24 months, these rates dropped to 32 % and 21 %.
Over a median follow - up of 12.5 months, 37 % of pemetrexed patients completed more than 6 cycles of the drug, compared to 18 % of placebo patients.
Serious neutropenia occurred in 5.8 % of pemetrexed patients and in no placebo patients.
Response rates measured at weeks 8 and 10 revealed that 49.2 percent of treatment patients achieved a clinical response, compared to 26.7 percent of placebo patients.